The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
high-affinity glutamate and neutral amino acid transporter (SLC1A1, SLC1A2, SLC1A3, SLC1A4, SLC1A5, SLC1A6, SLC1A7) facilitative GLUT transporter (SLC2A1, SLC2A2, SLC2A3, SLC2A4, SLC2A5, SLC2A6, SLC2A7, SLC2A8, SLC2A9, SLC2A10, SLC2A11, SLC2A12, SLC2A13, SLC2A14) heavy subunits of heterodimeric amino acid transporters (SLC3A1, SLC3A2) bicarbonate transporter (SLC4A1, SLC4A2, SLC4A3, SLC4A4, SLC4A5, SLC4A6, SLC4A7, SLC4A8, SLC4A9, SLC4A10, SLC4A11) sodium glucose cotransporter (SLC5A1, SLC5A2, SLC5A3, SLC5A4, SLC5A5, SLC5A6, SLC5A7, SLC5A8, SLC5A9, SLC5A10, SLC5A11, SLC5A12) sodium- and chloride-dependent sodium:neurotransmitter symporters (SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A6, SLC6A7, SLC6A8, SLC6A9, SLC6A10, SLC6A11, SLC6A12, SLC6A13, SLC6A14, SLC6A15, SLC6A16, SLC6A17, SLC6A18, SLC6A19, SLC6A20) cationic amino acid transporter/glycoprotein-associated cationic amino acid transporters (SLC7A1, SLC7A2, SLC7A3, SLC7A4) glycoprotein-associated/light or catalytic subunits of heterodimeric amino acid transporters (SLC7A5, SLC7A6, SLC7A7, SLC7A8, SLC7A9, SLC7A10, SLC7A11, SLC7A13, SLC7A14) Na+/Ca2+ exchanger (SLC8A1, SLC8A2, SLC8A3) Na+/H+ exchanger (SLC9A1, SLC9A2, SLC9A3, SLC9A4, SLC9A5, SLC9A6, SLC9A7, SLC9A8, SLC9A9, SLC9A10, SLC9A11, SLC9B1, SLC9B2) sodium bile salt cotransport (SLC10A1, SLC10A2, SLC10A3, SLC10A4, SLC10A5, SLC10A6, SLC10A7) proton coupled metal ion transporter (SLC11A1, SLC11A2) electroneutral cation-Cl cotransporter (SLC12A1, SLC12A2, SLC12A3, SLC12A4, SLC12A5, SLC12A6, SLC12A7, SLC12A8, SLC12A9) Na+-sulfate/carboxylate cotransporter (SLC13A1, SLC13A2, SLC13A3, SLC13A4, SLC13A5) urea transporter (SLC14A1, SLC14A2) proton oligopeptide cotransporter (SLC15A1, SLC15A2, SLC15A3, SLC15A4) monocarboxylate transporter (SLC16A1, SLC16A2, SLC16A3, SLC16A4, SLC16A5, SLC16A6, SLC16A7, SLC16A8, SLC16A9, SLC16A10, SLC16A11, SLC16A12, SLC16A13, SLC16A14) vesicular glutamate transporter (SLC17A1, SLC17A2, SLC17A3, SLC17A4, SLC17A5, SLC17A6, SLC17A7, SLC17A8, SLC17A9) vesicular amine transporter (SLC18A1, SLC18A2, SLC18A3) folate/thiamine transporter (SLC19A1, SLC19A2, SLC19A3) type III Na+-phosphate cotransporter (SLC20A1, SLC20A2) organic anion transporting subfamily 1 (SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1) subfamily 2 (SLCO2A1, SLCO2B1) subfamily 3 (SLCO3A1) subfamily 4 (SLCO4A1, SLCO4C1) subfamily 5 (SLCO5A1) subfamily 6 (SLCO6A1) organic cation/anion/zwitterion transporter (SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5, SLC22A6, SLC22A7, SLC22A8, SLC22A9, SLC22A10, SLC22A11, SLC22A12, SLC22A13, SLC22A14, SLC22A15, SLC22A16, SLC22A17, SLC22A18, SLC22A18AS, SLC22A19, SLC22A20, SLC22A23, SLC22A24, SLC22A25, SLC22A31) Na+-dependent ascorbic acid transporter (SLC23A1, SLC23A2, SLC23A3, SLC23A4) Na+/(Ca2+-K+) exchanger (SLC24A1, SLC24A2, SLC24A3, SLC24A4, SLC24A5, SLC24A6) mitochondrial carrier (SLC25A1, SLC25A2, SLC25A3, SLC25A4, SLC25A5, SLC25A6, UCP1(SLC25A7), UCP2(SLC25A8), UCP3(SLC25A9), SLC25A10, SLC25A11, SLC25A12, SLC25A13, SLC25A14, SLC25A15, SLC25A16, SLC25A17, SLC25A18, SLC25A19, SLC25A20, SLC25A21, SLC25A22, SLC25A23, SLC25A24, SLC25A25, SLC25A26, SLC25A27, SLC25A28, SLC25A29, SLC25A30, SLC25A31, SLC25A32, SLC25A33, SLC25A34, SLC25A35, SLC25A36, SLC25A37, SLC25A38, SLC25A39, SLC25A40, SLC25A41, SLC25A42, SLC25A43, SLC25A44, SLC25A45, SLC25A46), SLC25A47, SLC25A48, MTCH1(SLC25A49), MTCH2(SLC25A50), SLC25A51, SLC25A52, SLC25A53 multifunctional anion exchanger (SLC26A1, SLC26A2, SLC26A3, SLC26A4, SLC26A5, SLC26A6, SLC26A7, SLC26A8, SLC26A9, SLC26A10, SLC26A11) fatty acid transport proteins (SLC27A1, SLC27A2, SLC27A3, SLC27A4, SLC27A5, SLC27A6) Na+-coupled nucleoside transport (SLC28A1, SLC28A2, SLC28A3) facilitative nucleoside transporter (SLC29A1, SLC29A2, SLC29A3, SLC29A4) zinc transporter (SLC30A1, SLC30A2, SLC30A3, SLC30A4, SLC30A5, SLC30A6, SLC30A7, SLC30A8, SLC30A9, SLC30A10) copper transporter (SLC31A1, SLC31A2) vesicular inhibitory amino acid transporter (SLC32A1) Acetyl-CoA transporter (SLC33A1) type II Na+-phosphate cotransporter (SLC34A1, SLC34A2, SLC34A3) nucleotide-sugar transporter subfamily A (SLC35A1, SLC35A2, SLC35A3, SLC35A4, SLC35A5) subfamily B (SLC35B1, SLC35B2, SLC35B3, SLC35B4) subfamily C (SLC35C1, SLC35C2) subfamily D (SLC35D1, SLC35D2, SLC35D3) subfamily E (SLC35E1, SLC35E2A, SLC35E2B, SLC35E3, SLC35E4) subfamily F (SLC35F1, SLC35F2, SLC35F3, SLC35F4, SLC35F5) subfamily G (SLC35G1, SLC35G3, SLC35G4, SLC35G5, SLC35G6) proton-coupled amino acid transporter (SLC36A1, SLC36A2, SLC36A3, SLC36A4) sugar-phosphate/phosphate exchanger (SLC37A1, SLC37A2, SLC37A3, SLC37A4) System A & N, sodium-coupled neutral amino acid transporter (SLC38A1, SLC38A2, SLC38A3, SLC38A4, SLC38A5, SLC38A6, SLC38A7, SLC38A8, SLC38A9, SLC38A10, SLC38A11) metal ion transporter (SLC39A1, SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A8, SLC39A9, SLC39A10, SLC39A11, SLC39A12, SLC39A13, SLC39A14) basolateral iron transporter (SLC40A1) MgtE-like magnesium transporter (SLC41A1, SLC41A2, SLC41A3) Ammonia transporter (RHAG(SLC42A1), RHBG(SLC42A2), RHCG(SLC42A3)) Na+-independent, system-L like amino acid transporter (SLC43A1, SLC43A2, SLC43A3) Choline-like transporter (SLC44A1, SLC44A2, SLC44A3, SLC44A4, SLC44A5) Putative sugar transporter (SLC45A1, SLC45A2, SLC45A3, SLC45A4) Folate transporter (SLC46A1, SLC46A2, SLC46A3) multidrug and toxin extrusion (SLC47A1, SLC47A2) Heme transporter family (SLC48A1) Heme transporter (FLVCR1(SLC49A1), FLVCR2(SLC49A2), SLC49A3, SLC49A4) Sugar efflux transporters of the SWEET family (SLC50A1) Transporters of steroid-derived molecules (SLC51A, SLC51B) Riboflavin transporter family RFVT/SLC52 (SLC52A1, SLC52A2, SLC52A3) Phosphate carriers (XPR1(SLC53A1)) Mitochondrial pyruvate carriers (MPC1(SLC54A1), MPC2(SLC54A2), MPC1L(SLC54A3)) Mitochondrial cation/proton exchangers (LETM1(SLC55A1), LETM2(SLC55A2), LETMD1(SLC55A3)) Sideroflexins (SFXN1(SLC56A1), SFXN2(SLC56A2), SFXN3(SLC56A3), SFXN4(SLC56A4), SFXN5(SLC56A5)) NiPA-like magnesium transporter family (NIPA1(SLC57A1), NIPA2(SLC57A2), NIPAL1(SLC57A3), NIPAL2(SLC57A4), NIPAL3(SLC57A5), NIPAL4(SLC57A6)) MagT-like magnesium transporter family (MAGT1(SLC58A1), TUSC3(SLC58A2)) Sodium-dependent lysophosphatidylcholine symporter family (MFSD2A(SLC59A1), MFSD2B(SLC59A2)) Glucose transporters (MFSD4A(SLC60A1), MFSD4B(SLC60A2)) Molybdate transporter family (MFSD5(SLC61A1)) Pyrophosphate transporters (ANKH(SLC62A1)) Sphingosine-phosphate transporters (SPNS1(SLC63A1), SPNS2(SLC63A2), SPNS3(SLC63A3)) Golgi Ca2+/H+ exchangers (TMEM165(SLC64A1)) NPC-type cholesterol transporters (NPC1(SLC65A1), NPC1L1(SLC65A2)) Cationic amino acid exporters (SLC66A1, SLC66A2, SLC66A3, CTNS(SLC66A4), MPDU1(SLC66A5))
Kimon Georgiev established the political circle "Zveno" with Damyan Velchev in 1927, firstly as a non-partisan organization that aims to improve the socio-political climate in the country. It proclaimed its support for authoritarian power, raised above the strictly party interests, with national purpose. The fascists influence on the Zveno is undisputed, but its not characterized as fascist, but a corporate statism in which it mainly drew inspiration from Italian fascism. Georgiev ceased ties with the Democratic Alliance in 1930 and after the 1931 Bulgarian parliamentary election, he was no longer a deputy of his group. He became a leader of the Zveno and in the beginning of 1932, a newspaper Izgrev was published with one of the editors being Georgiev himself. He published articles in which he criticized communism and the Soviet Union, as well as declaring for a strong government "in the name of order and state intervention in economic life." The primary component of Zveno's ideology was anti-communism, which embraced strong "supra-party" authoritarian bourgeois power of the fascist variety while rejecting the bourgeois democratic system of governance. The bulk of Zveno members joined Aleksander Tsankov's Popular Social Movement in January 1934, but a smaller group led by Kimon Georgiev kept the group operating independently. Zveno was a little organization with little social interaction. It made touch with the Military League, which was once more planning a violent change of government.
=== Participation === Individuals with dwarfism are capable of actively participating in various aspects of society. They have access to education and sports, and can pursue careers, engaging in a wide range of professions.
In MASS, the sample is spun at several kilohertz around an axis that makes the so-called magic angle θm (which is ~54.74°, where 3cos2θm-1 = 0) with respect to the direction of the static magnetic field B0; as a result of such magic angle sample spinning, the broad chemical shift anisotropy bands are averaged to their corresponding average (isotropic) chemical shift values. Correct alignment of the sample rotation axis as close as possible to θm is essential for cancelling out the chemical-shift anisotropy broadening. There are different angles for the sample spinning relative to the applied field for the averaging of electric quadrupole interactions and paramagnetic interactions, correspondingly ~30.6° and ~70.1°. In amorphous materials, residual line broadening remains since each segment is in a slightly different environment, therefore exhibiting a slightly different NMR frequency. Line broadening or splitting by dipolar or J-couplings to nearby 1H nuclei is usually removed by radio-frequency pulses applied at the 1H frequency during signal detection. The concept of cross polarization developed by Sven Hartmann and Erwin Hahn was utilized in transferring magnetization from protons to less sensitive nuclei by M.G. Gibby, Alex Pines and John S. Waugh. Then, Jake Schaefer and Ed Stejskal demonstrated the powerful use of cross polarization under MAS conditions (CP-MAS) and proton decoupling, which is now routinely employed to measure high-resolution spectra of low-abundance and low-sensitivity nuclei, such as carbon-13, silicon-29, or nitrogen-15, in solids.
Blood-thinning agents are divided into two groups, antiplatelet drugs and anticoagulants. They are indicated to facilitate smooth blood flow within blood vessels by preventing the formation of blood clots and retarding their growth. Blood clots are formed to prevent an injured blood vessel from excessive bleeding by a mechanism called hemostasis. The body has intrinsic mechanisms to dissolve the blood clot as the injury heals. However, it can be dangerous when clots do not dissolve naturally and develop within vessels, also known as thrombosis. Hence, blood-thinning medications can be prescribed to reduce the risk of cardiovascular diseases led by blood clots, such as myocardial infarction (heart attack), ischemic stroke, and venous thromboembolism. Haemorrhage (internal bleeding) is the most prominent side effect of blood-thinning therapy. Concomitant use of drugs that increase the risk of bleeding is not recommended. Meanwhile, patients should receive education about proper management of cuts, bruises and nosebleeds. The agents can be classified according to different mechanisms of action.
Sources: en.wikipedia.org
== Nutrition == Boletus edulis mushrooms are 9% carbohydrates, 3% fat, and 7% protein (table). Fresh mushrooms consist of over 80% moisture, although reported values tend to differ somewhat as moisture content can be affected by environmental temperature and relative humidity during growth and storage. The carbohydrate component contains the monosaccharides glucose, mannitol and α,α-trehalose, the polysaccharide glycogen, and the water-insoluble structural polysaccharide chitin, which accounts for up to 80–90% of dry matter in mushroom cell walls. Chitin, hemicellulose, and pectin-like carbohydrates—all indigestible by humans—contribute to the high proportion of insoluble fibre in B. edulis. The total lipid, or crude fat, content makes up 3% of the dry matter of the mushroom. The proportion of fatty acids (expressed as a % of total fatty acids) are: linoleic acid 42%, oleic acid 36%, palmitic acid 10%, and stearic acid 3%. A comparative study of the amino acid composition of eleven Portuguese wild edible mushroom species showed Boletus edulis to have the highest total amino acid content. B. edulis mushrooms are rich in the dietary minerals, sodium, iron, calcium, and magnesium, with amounts varying according to the mushroom component and to soil composition in the geographic region of China where they were sampled. They also have high content of B vitamins and tocopherols. B. edulis contains appreciable amounts of selenium, a trace mineral, although the bioavailability of mushroom-derived selenium is low.
== Biodistribution and mechanisms of action == Lithium compartmentalization was studied in 11 biosubstrates of rats when lithium ascorbate was taken at a dose of 1000 mg/kg. As part of a tubeless analysis of the dynamics of concentrations in whole blood, the following values of the pharmacokinetic parameters of lithium ascorbate were obtained: Cmax=50.59 µg/l, tmax=1.50 h, Clast=33.7 µg/l, AUCt=1750 µg/l*h, MRTt=22.9 h, Lz=0.005 1/h, T1/2=141 h, CL=0.029 l/h, Vd=5.9 l. Multichamber pharmacokinetic analysis showed that the stabilization of lithium levels in the blood is maintained by a special "depot" of lithium, apparently consisting of the aorta, femur and brain. Application of the method of functional linkage analysis suggested that the targeted accumulation of ascorbate anion in cells is due to the activity of vitamin C transport proteins SLC23A1, SLC23A2, SLC23A3. At the same time, lithium ions and ascorbate exhibit a synergistic effect. The main effects of lithium include the support of normal excitability central nervous system: by preventing excessive concentration of norepinephrine, regulation of sodium concentration in muscle cells (which is important for the tone of blood vessels), sensitivity of neurons to dopamine, which reduces the negative impact of stress.
==== Dopamine ==== In certain brain regions, amphetamine increases the concentration of dopamine in the synaptic cleft by modulating DAT through several overlapping processes. Amphetamine can enter the presynaptic neuron either through DAT or, to a lesser extent, by diffusing across the neuronal membrane directly. As a consequence of DAT uptake, amphetamine produces competitive reuptake inhibition at the transporter. Upon entering the presynaptic neuron, amphetamine provokes the release of Ca2+ from endoplasmic reticulum stores, an effect that raises intracellular calcium to levels sufficient for downstream kinase-dependent signalling. In parallel, amphetamine also increases intracellular cAMPTooltip cyclic adenosine monophosphate, which activates protein kinase A (PKA) and protein kinase C (PKC), whilst elevated intracellular Ca2+ activates PKC alone. Phosphorylation of DAT by either kinase induces transporter internalization (non-competitive reuptake inhibition), but PKC-mediated phosphorylation alone induces the reversal of dopamine transport through DAT (i.e., dopamine efflux). TAAR1 has been identified as a biomolecular target of amphetamine that initiates some of amphetamine's kinase-dependent signaling cascades. When TAAR1 signals via Gs-coupled receptors, intracellular cAMP increases through adenylyl cyclase activation and activates PKA and PKC, in turn phosphorylating DAT.
== Uses == The plant is native to the Caribbean, where the Taíno people were the first recorded peoples to use it and cultivate it. In 1560, Jean Nicot de Villemain, then French ambassador to Portugal, brought tobacco seeds and leaves as a "wonder drug" to the French court. In 1586 the botanist Jaques Dalechamps gave the plant the name of Herba nicotiana, which was also adopted by Linné. It was considered a decorative plant at first, then a panacea, before it became a common snuff and tobacco plant. Tobacco arrived in Africa at the beginning of the 17th century. The leaf extract was a popular pest control method up to the beginning of the 20th century. In 1851, the Belgian chemist Jean Stas documented the use of tobacco extract as a murder poison. The Belgian count Hippolyte Visart de Bocarmé had poisoned his brother-in-law with tobacco leaf extract in order to acquire some urgently needed money. This was the first exact proof of alkaloids in forensic medicine. It is now commercially cultivated worldwide. All parts of the plant contain nicotine, which can be extracted and used as an insecticide. The dried leaves can also be used; they remain effective for 6 months after drying. The juice of the leaves can be rubbed on the body as an insect repellent. The leaves can be dried and chewed as an intoxicant. The dried leaves are also used as snuff or are smoked. This is the main species that is used to make cigarettes, cigars, and other products. A drying oil is obtained from the seed. Other varieties are cultivated as ornamental plants.
Sources: en.wikipedia.org
=== Decreased lactose content === During the fermentation process, bacteria and yeast break lactose down into glucose and galactose. As a result of the fermentation, lactose levels are decreased by 20–30% with respect to the initial lactose levels present in the milk. One study found that when people with lactose intolerance consumed the same amount of lactose in milk, kefir or yogurt products, the latter two showed significantly reduced symptoms of lactose intolerance during the first 8 hours after consumption. This result suggests that yogurt and kefir might be suitable for people with lactose intolerance. However, the long-term impact of kefir consumption on lactose intolerance has not been studied. It has also been shown that fermented milk products have a slower transit time than milk, which may further improve lactose digestion.
Registered voters: 425,305, valid: 371,189, turnout: 87.3% To honour the exceptionally high percentage of pro-German votes in the district of Oletzko, with 2 votes for Poland compared to 28,625 for Germany, the district town Marggrabowa (i.e. Margrave town) was renamed "Treuburg" (TreueGerman = "loyalty") in 1928, with the district following this example in 1933. In the villages of Lubstynek (Klein Lobenstein), Czerlin (Klein Nappern) and Groszki (Groschken) in the District of Osterode in East Prussia (Ostróda), situated directly at the border, the majority voted for Poland and joined Poland after the plebiscite. Other Polish-majority villages were scarce but would have been more numerous if they had not been surrounded by Mazurian German disposed villages, which made a geographical connection with Poland improbable and so votes for Poland would not be useful. The strategic importance of the Prussian Eastern Railway line Danzig-Warsaw passing through the area of Soldau in the Neidenburg District caused it to be transferred to Poland without a plebiscite; it was renamed Działdowo.[1]
saturation hybridization An in vitro nucleic acid hybridization reaction in which one polynucleotide component (either DNA or RNA) is supplied in great excess relative to the other, causing all complementary sequences in the other polynucleotide to pair with the excess sequences and form hybrid duplex molecules.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.